Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zevalin European approval delayed

Idec (IDPH) said European approval for its Zevalin non-Hodgkin's lymphoma (NHL) radioimmunotherapy has been delayed due to compliance

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE